Skip to Content
Merck
All Photos(1)

Documents

Safety Information

LO4200

Sigma-Aldrich

LOPAC®1280 - Small Scale

International Version

Synonym(s):

Library of Pharmacologically Active Compounds - small scale

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

EC Number:
200-664-3
UNSPSC Code:
12352200
NACRES:
NA.77

form

liquid

shipped in

dry ice

storage temp.

−20°C

Looking for similar products? Visit Product Comparison Guide

General description

Compounds are arranged in 96-well format in 16 racks of 80, one compound per well (25 μl at 10 mM in DMSO in archival storage racks).

Application

Library of pharmacologically active compounds LOPAC®1280 - small scale has been used to screen for the suppressors of niclosamide- and nigericin-induced interleukin (IL-1β) release.

Features and Benefits

Includes the latest, drug-like molecules in the fields of Cell Signaling & Neuroscience:

  • Apoptosis
  • G Proteins & Cyclic Nucleotides
  • Gene Regulation & Expression
  • Ion Channels
  • Lipid Signaling
  • Multi-Drug Resistance
  • Neurotransmission
  • Phosphorylation
SDFile provided to construct a database containing:
  • Structure
  • Primary Name
  • Secondary Name
  • Pharmacological Activity
  • Product Number
  • Rack Position

Other Notes

For sale outside of the U.S. only. U.S. customers should refer to Product Code LO4100.

Legal Information

LOPAC is a registered trademark of Merck KGaA, Darmstadt, Germany

Signal Word

Danger

Hazard Classifications

Acute Tox. 2 Dermal - Acute Tox. 2 Inhalation - Acute Tox. 2 Oral - Aquatic Acute 1 - Aquatic Chronic 1 - Carc. 1A - Eye Dam. 1 - Lact. - Muta. 1B - Repr. 1A - Resp. Sens. 1 - Skin Corr. 1B - Skin Sens. 1 - STOT RE 2 - STOT SE 2

Storage Class Code

6.1A - Combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials

Flash Point(F)

188.6 °F

Flash Point(C)

87 °C

Regulatory Listings

Regulatory Listings are mainly provided for chemical products. Only limited information can be provided here for non-chemical products. No entry means none of the components are listed. It is the user’s obligation to ensure the safe and legal use of the product.

PDSCL

Please refer to KIT Component information

PRTR

Please refer to KIT Component information

FSL

Please refer to KIT Component information

ISHL Indicated Name

Please refer to KIT Component information

ISHL Notified Names

Please refer to KIT Component information

Cartagena Act

Please refer to KIT Component information

JAN Code

キットコンポーネントの情報を参照してください

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Laura M Alcântara et al.
Molecules (Basel, Switzerland), 25(11) (2020-06-04)
High genetic and phenotypic variability between Leishmania species and strains within species make the development of broad-spectrum antileishmanial drugs challenging. Thus, screening panels consisting of several diverse Leishmania species can be useful in enabling compound prioritization based on their spectrum
Anzar Asad et al.
Basic & clinical pharmacology & toxicology, 133(4), 364-377 (2023-07-03)
Adhesion G protein-coupled receptors (GPCRs) are an underrepresented class of GPCRs in drug discovery. We previously developed an in vivo drug screening pipeline to identify compounds with agonist activity for Adgrg6 (Gpr126), an adhesion GPCR required for myelination of the
Niclosamide activates the NLRP3 inflammasome by intracellular acidification and mitochondrial inhibition
Tran UT and Kitami T
Communications biology, 2(1), 2-2 (2019)
High-throughput screening identifies compounds that enhance lentiviral transduction.
Johnston JM, Denning G, Moot R, et al.
Gene Therapy, doi:10-doi:10 (2014)
Eleanor Star et al.
Oncogenesis, 10(5), 36-36 (2021-05-05)
Alternative splicing of the vascular endothelial growth factor A (VEGF-A) terminal exon generates two protein families with differing functions. Pro-angiogenic VEGF-Axxxa isoforms are produced via selection of the proximal 3' splice site of the terminal exon. Use of an alternative
View All Related Papers

Articles

LOPAC®1280 Small Molecules Screening

Explore compound library screening options with our Pharmacologically Active Compounds portfolio.

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service